At a glance
| Item | Position |
|---|---|
| Act and provision | Income-tax Act, 2025, section 45 |
| Official heading | Expenditure on scientific research. |
| Location | Chapter IV, Part D: Profits and gains of business or profession |
| Legal status | Enacted and operative; editorial draft |
| General commencement | 1 April 2026 |
| Legal function | Deductions for own research and approved research payments |
Choose the research route before measuring the deduction
Section 45 does not create one interchangeable deduction for everything called R&D. Subsection (1) covers scientific research related to the taxpayer’s business. Subsection (2) concerns an approved in-house R&D facility of a qualifying company. Subsection (3) covers sums paid to specified research recipients and programmes. The section allows the qualifying expenditure or sum; its operative text does not provide a blanket 150% or 200% multiplier. Historical weighted-deduction figures should not be imported into this Act. S1, section 45(1)–(3)
Scientific research means extending knowledge in natural or applied science, including agriculture, animal husbandry and fisheries. The definition includes expenditure on conducting research or providing its facilities, but excludes acquiring rights in or arising from research. Business-related research includes research that may extend or facilitate that business and medical research specially related to its workers’ welfare. Buying an existing research right therefore requires a different analysis from funding actual research. S1, section 66(27)
Own-business research and the three-year pre-commencement window
Subsection (1)(a) permits revenue expenditure and capital expenditure on business-related scientific research, but excludes land acquired separately or as part of a property. “Land” includes an interest in land. Unlike subsection (2), this capital route does not itself exclude the research building; eligibility still depends on its research use and the other provisions. S1, section 45(1)(a) and (11)(d)
For the three years immediately before business commencement, qualifying non-capital expenditure is limited to research employees’ salaries and materials used in that research, to the extent certified by the prescribed authority. It is deemed incurred in the commencement tax year. Rule 29(1) identifies the Principal Chief Commissioner of Income Tax (Exemptions), acting in concurrence with the Secretary, Department of Scientific and Industrial Research (DSIR). Qualifying research capital expenditure in the same three-year window is also deemed incurred in the commencement year, subject to the land exclusion. This does not bring every historical startup expense into the deduction. S1, section 45(1)(b)–(c); S2, rule 29(1)
The salary definition adopts section 16 read with section 18, but omits section 16(e) perquisites and section 16(j) specified transferred provident-fund balances, and adapts the employee/employer references. Do not use an undifferentiated payroll total when preparing the pre-commencement certification claim. S1, section 45(11)(b)
Approved in-house company R&D
A company in biotechnology, or manufacturing or producing an article or thing outside Schedule XIII, may use subsection (2) for expenditure on an approved in-house facility. Land and building cost are excluded. A company approved under subsection (3)(b)(ii) cannot claim this subsection (2) allowance. Expenditure allowed through this route cannot also be claimed under another provision. For drugs and pharmaceuticals, the section expressly includes clinical drug trials, obtaining regulatory approval under the stated laws and filing a patent application under the Patents Act, 1970. S1, section 45(2)(i)–(v)
Schedule XIII is a specific product list, including alcoholic spirits, tobacco products, cosmetics and toiletries, toothpaste and soap, specified aerated waters, confectionery and chocolates, gramophones and records, projectors, photographic goods, specified office machines other than computers, steel furniture, safes and strong-room goods, specified foam products, crown corks and pilfer-proof caps. Check the actual product against the Schedule; do not assume that all manufacturing companies qualify. S1, Schedule XIII
Under rule 29, the prescribed authority is the DSIR Secretary. The company enters the research-cooperation agreement through Form 11; approval is in Form 14, with a four-month decision period measured from the end of the application month and a hearing before rejection. A facility purely for market research, sales promotion, quality control, testing, commercial production, style changes or routine data collection does not qualify. S2, rule 29(2)
Maintain separate books for each approved facility, annual audit and financial-statement disclosure of capital and revenue research expenditure. Form 13 is the accountant’s report to DSIR by the prescribed return due date; the authority reports facility approval and quantified eligible expenditure in Parts A and B of Form 12, within the respective 120-day periods. Rule 29 also requires the audited accounts with the return. Facility assets must serve the approved purpose and cannot be disposed of without DSIR approval. An approval letter alone is therefore not the whole compliance file. S2, rule 29(2)(e)
Payments to research bodies: recipient and purpose matter
The three payment routes are summarised below. Keep evidence of payment, its research purpose or direction, and the approval applicable at the relevant time. S1, section 45(3)–(4)
| Route | Recipient and conditions |
|---|---|
| Section 45(3)(a) | Research association, university, college or institution for scientific research, or social-science/statistical research; the relevant recipient must be approved and notified under subsection (4)(b) |
| Section 45(3)(b) | Company registered in India with scientific research and development as its main object, approved by the prescribed authority |
| Section 45(3)(c) | National laboratory, university, IIT or approved specified person, with a specific direction for scientific research under an approved programme |
A national laboratory must function at national level under one of the listed bodies or departments (ICAR, ICMR, CSIR, DRDO, Electronics, Biotechnology or Atomic Energy) and have the required approval. A “specified person” also needs prescribed-authority approval. Institutional reputation, a charitable registration or a receipt alone is not the statutory approval for these routes. S1, section 45(11)(a) and (c)
Approval and donor reporting for associations, institutions and companies
Rules 32–35 govern Form 17 applications and recipient conditions. For the institutional route, apply to the jurisdictional Commissioner and send an acknowledged copy to Member (IT), CBDT; the Central Government issues the notification. For the company route, apply to the Commissioner and send an acknowledged copy to the jurisdictional Chief Commissioner, the approving authority under rule 35. Applications ordinarily precede the tax year from which approval is sought, with express accommodation for tax year 2026–27 and the establishment/incorporation year. Orders run for at most five tax years; the rules prescribe a decision within twelve months from the end of the quarter in which the application reaches Member (IT) for the institutional route or the Chief Commissioner for the company route and fresh applications at least three months before expiry. Rejection or withdrawal requires the prescribed hearing opportunity. S2, rules 32 and 35
Associations must have the relevant research as their sole object and undertake it themselves. Universities and institutions must conduct research through their own faculty or students. Approved companies undertake research through their own employees and assets. Applicable separate-account, audit, donation-use and research-report conditions continue after approval; non-genuine activities or non-compliance can lead to withdrawal. S2, rules 33–35
For subsection (3)(a) and (b) payments, rule 31 makes the recipient’s Form 15 statement and Form 16 donor certificate deduction conditions. Both are due by 31 May immediately following the donation tax year. Same-kind donations from a person are aggregated; joint donations are attributed in the stated proportions, or equally where none is specified. The return-verifying person under section 265 verifies Form 15. The payer should reconcile its receipt with the reported amount rather than treating reporting as irrelevant because the recipient files it. S2, rule 31
Programme approval is a separate route
Under rule 30, the sponsor applies in Form 7; approval is in Form 8, normally within two months from the end of the application month, for at most five tax years. The authority is the head of the national laboratory, university or IIT, or the Principal Scientific Adviser for an approved specified person. The recipient issues Form 9 as the payment receipt. Pure market research and the other routine activities listed in the rule are excluded. S2, rule 30(1)–(8)
Each approved programme needs separate accounts, annual audit and reporting to the sponsor’s jurisdictional Chief Commissioner. Form 10 reports progress and expenditure within three months of approval. Completion requires a joint research report and certificate, followed by the audited programme statement within six months. The authority cannot extend programme duration or approve cost escalation under this rule; asset disposal requires approval. A fresh approval application can be made at least three months before expiry. Retain the programme order as well as the payment receipt. S2, rule 30(7)–(9)
Later withdrawal, losses and subsequent asset events
A subsection (3) deduction cannot be denied merely because the recipient’s or programme’s approval is withdrawn after payment. That protection does not remove other conditions, such as payment, eligible purpose or reporting. S1, section 45(5)
Where an asset wholly or partly represents expenditure deducted under this section, section 33(3) depreciation is barred for the same or any other year. Unabsorbed capital-research deduction under subsection (1) follows section 33(11). Subsection (3)(c) payments cannot be deducted again elsewhere. If a research asset passes in amalgamation to an Indian company, the successor continues the section’s treatment. A later sale can engage the separate recovery rule in section 38(1)(c); the original deduction is not the end of the asset’s tax history. S1, section 45(6)–(8) and (10); section 38(1)(c)
Disputes about whether, or to what extent, an activity or asset constitutes scientific research are referred by the Board to the Central Government for subsection (3)(a), and otherwise to the prescribed authority; the respective decision is final under subsection (9). S1, section 45(9)
Check the tax regime before finalising a payment deduction
Sections 202(2)(a)(ix) and 205(1)(b), in their applicable regimes, exclude deductions under section 45(3)(a), (b) and (c). These references do not themselves exclude every own-business research expense under subsections (1) and (2). Establish the taxpayer’s regime and exact research route before promising a tax benefit. S1, sections 202(2)(a)(ix) and 205(1)(b)
Earlier approvals and tax benefits
Earlier approvals, notifications, agreements and schemes continue only so far as consistent with the corresponding 2025 Act provisions under section 536(2)(j). Section 536(2)(h) also preserves later inclusion of sums relieved under the repealed Act where its conditions require that inclusion; the new Act does not erase an earlier benefit’s continuing tax consequences. S1, section 536(2)(h)–(j)
Hypothetical illustrations
Pre-commencement salary and materials
Facts: A business begins in tax year 2026–27. Within the preceding three years it spent ₹4,00,000 on qualifying research salaries and ₹2,00,000 on research materials; the prescribed authority certifies ₹5,00,000 in aggregate.
Assumptions: The research relates to this business. Salary is measured using the modified statutory definition. No amount is capital expenditure or claimed elsewhere.
Question: What enters the commencement-year claim under section 45(1)(b)?
Analysis: The claim is limited to the certified research expenditure, ₹5,00,000, rather than the entire ₹6,00,000 submitted. The statutory deeming places it in 2026–27.
Conclusion: ₹5,00,000 is treated as incurred in the commencement tax year under this route. S1, S2
Research land cannot be included in the capital claim
Facts: An operating business buys research equipment for ₹8,00,000 and a plot of land for ₹3,00,000.
Assumptions: The equipment is wholly for scientific research related to the business. All relevant conditions under section 45(1) are satisfied. There are no other cost adjustments or competing deductions.
Question: What is the eligible expenditure under section 45(1)(a)(i)?
Analysis: The land component is expressly excluded. ₹11,00,000 total spending − ₹3,00,000 land = ₹8,00,000 eligible capital research expenditure.
Conclusion: The ₹8,00,000 enters this capital-deduction route; section 33(3) depreciation cannot also be claimed for that deducted asset. S1
Reader questions
Does later cancellation of approval automatically cancel an earlier payment deduction?
No. Section 45(5) protects against denial merely for withdrawal after payment. The original payment and all other applicable conditions must still be established. S1
Are land and building treated identically under all research routes?
No. Own-business capital research under subsection (1) excludes land, including interests in land. Approved in-house company R&D under subsection (2) excludes both land and building cost. S1